Survival Analysis Of 176 Cases Of Advanced Non-small Cell Lung Cancer

ObjectiveThis is a retrospective study among 176 patients with stage Ⅲb/Ⅳ non-small cell lung cancer. We’d like to know the median overall survival and survival rate within 5 years of the patients treated in our department. What’s more, we study further among the subgroups to investigate the overall survival stratified by EGFR gene mutation status, independent prognostic factors and how TCM therapy contributes to overall survival.MethodsWe collected the cases retrospectively from January 1st,2012 to December 31st,2013 treated by Oncology Department One of GD Hospital of TCM. These 176 cases are patients who diagnosed as stage ⅢB/Ⅳ NSCLC. Some information were added by telephone follow-up. The primary end point is OS. The calculation of OS, univariate and multivariate survival analysis is performed by SPSS 17.0.Results1.1. The overall survival is 15 months (65.9 maturity) and is 19 months(69.7% maturity) if we kick those whose overall survival is less than 3 months.The 1.3 and 5 year survival rate is 56%±4%,19%±4%, and 4%±3%.2. The kaplan-Meier univariate survival analysis shows statistical OS difference among the subgroups of age, sex, smoking history, whether liver metastasis at diagnosis,time when first treated,treatment and whether first treated in our department.3. The overall survival in EGFR wild type patients is 9 months, in EGFR mutation patients is 20 months (59.4% maturity) and in EGFR unknown patients is 18 months (log rank P=0.352).4. The cox regression of multivariate survival analysis shows the independent poor prognosis factors are smoking history, liver metastasis at diagnosis, and not accepted 2 more lines of therapy.5. The patients’overall survival is 13 months(64.7% maturity) who treated first at our department.35(29.4%) patients’PS is score 2 or above among them. Compare with those first treated in other hospital, they have a higher portion in 2 or more metastasis at diagnosis, liver metastasis at diagnosis, not receive 2 or more lines therapy and not have received chemotherapy or TKI therapy. 6. The overall survival among those who haven’t received chemotherapy or TKI therapy is 4 months. The OS is 6 months if we kick those whose overall survival is less than 3 months and the OS is 6 months versus 4 months (log rank P=0.858) compared our department first treated with other hospital first treated.Conclusion1.1.THe overall survival is 15 months(65.9 maturity). The 1,3 and 5 year survival rate is 56%±4%,19%±4%, and 4%±3%.The overall survival in EGFR mutaion patients is 20 months(59.4% maturity),in EGFR wild type patients is 9 months, and in EGFR unknown patients is 18 months (log rank P=0.352)2. The independent poor prognosis factors are smoking history, liver metastasis at diagnosis, and not accepted 2 more lines of therapy.3. It seems that TCM therapy shows some survival benefit among the patients who haven’t receive chemotherapy or TKI drugs.